{"product_id":"sunpharma-swot-analysis","title":"Sun Pharma Industries SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSun Pharma’s global scale, strong R\u0026amp;D pipeline, and diversified generics portfolio position it well against regulatory and pricing pressures, but patent cliffs and emerging-market volatility are notable risks; discover how these forces interact and what they mean for investors. Purchase the full SWOT analysis to receive a research-backed, editable Word and Excel package with strategic recommendations and financial context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership in India\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma is India’s largest pharma firm, holding about 8.5% domestic market share in FY2024 and leading in chronic therapies like cardiology and psychiatry; this scale drives Rs 34,200 crore (₹342 billion) India revenue in FY2024. \u003c\/p\u003e\n\u003cp\u003eThe company uses a 200,000+ strong field force and a distribution network covering 900,000 outlets to reach urban and rural patients, boosting prescription share and inventory turnover. \u003c\/p\u003e\n\u003cp\u003eStable Indian cash flows—~60% of consolidated EBITDA in 2024—fund global acquisitions and R\u0026amp;D spends, with R\u0026amp;D at ~4.2% of sales in FY2024, enabling high-cost drug development and geographic expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Specialty Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma shifted from generics to specialty drugs in dermatology, ophthalmology and oncology, with branded products Ilumya (psoriasis) and Cequa (dry eye) driving growth; specialty sales rose to about 35% of consolidated revenue in FY2024 (₹~33,000 crore total revenue).\u003c\/p\u003e\n\u003cp\u003eInvestments in complex molecules and formulation R\u0026amp;D created high entry barriers—Sun’s specialty EBITDA margin reached roughly 28% vs 18% for generics in FY2024—reducing exposure to generic price erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Vertical Integration Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSun Pharma manufactures about 60% of its Active Pharmaceutical Ingredients (APIs) in-house, cutting third-party dependence and lowering COGS; gross margin improved to 63.1% in FY2024 (year ended Mar 2024). This vertical integration tightens quality control, supports faster regulatory filings, and helped cut time-to-market for 12 new product launches across the US and emerging markets in 2024, strengthening its competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Investment in Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSun Pharma Industries consistently invests about 7–8% of revenue in R\u0026amp;D (INR ~5.2–6.0 billion in FY2024), targeting complex generics, specialty delivery systems, and new drug applications to sustain innovation.\u003c\/p\u003e\n\u003cp\u003eThat spend supports a robust pipeline with over 60 ANDA\/NDA\/MAA filings globally as of Dec 31, 2024, positioning the company for steady launches and long-term growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend ~7–8% of revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eINR ~5.2–6.0 billion R\u0026amp;D FY2024\u003c\/li\u003e\n\u003cli\u003e~60 regulatory filings globally (Dec 31, 2024)\u003c\/li\u003e\n\u003cli\u003eFocus: complex generics, specialty delivery, new drug apps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Compliance Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSun Pharma operates over 47 manufacturing sites across 9 countries and sells in 100+ markets, giving a diversified production base that reduces single‑market risk and supports local registration and supply needs.\u003c\/p\u003e\n\u003cp\u003eThis footprint helps optimize tax and logistics — regional hubs lower distribution costs — and in 2024 the company reported consolidated revenues of INR 38,500 crore, underpinning capacity to bid large government tenders.\u003c\/p\u003e\n\u003cp\u003eThe scale and regulatory compliance across US FDA, EMA, and CDSCO approvals enable participation in international procurement programs and tenders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e47+ sites, 9 countries, 100+ markets\u003c\/li\u003e\n\u003cli\u003eINR 38,500 crore revenue (FY 2024)\u003c\/li\u003e\n\u003cli\u003eMultiple US FDA\/EMA\/CDSCO approvals\u003c\/li\u003e\n\u003cli\u003eCapacity for large government tenders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSun Pharma: India’s No.1 Pharma—Strong Specialty, Robust R\u0026amp;D \u0026amp; Global Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSun Pharma is India’s largest pharma firm (≈8.5% domestic share, FY2024) with FY2024 consolidated revenue INR 38,500 crore and India revenue INR 34,200 crore, strong specialty mix (~35% of revenue) and ~28% specialty EBITDA margin. It owns 47+ sites in 9 countries, 900,000 outlets reach, 200,000+ field force, ~60% API in‑house, R\u0026amp;D ~7–8% of revenue with ~60 filings (Dec 31, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsol. revenue\u003c\/td\u003e\n\u003ctd\u003eINR 38,500 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia revenue\u003c\/td\u003e\n\u003ctd\u003eINR 34,200 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty mix\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty EBITDA\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e7–8% rev (~INR 5.2–6.0 bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory filings\u003c\/td\u003e\n\u003ctd\u003e~60 (Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint\u003c\/td\u003e\n\u003ctd\u003e47+ sites, 9 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField force \/ outlets\u003c\/td\u003e\n\u003ctd\u003e200,000+ \/ 900,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Sun Pharma Industries, highlighting its core strengths in global generics and R\u0026amp;D, operational and regulatory weaknesses, market expansion and portfolio diversification opportunities, and competitive, patent and regulatory threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Sun Pharma for rapid strategic alignment and executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Regulatory Compliance Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma has faced repeated US FDA issues—warning letters or import alerts at sites including Halol and Mohali—causing product launches to slip; a 2023 FDA observation campaign led to remediation costs estimated at over $150m in 2023–24.\u003c\/p\u003e\n\u003cp\u003eThese setbacks can delay revenue recognition: Sun Pharma reported FY2024 revenue growth of 7% but cited regulatory remediation as a drag on US injectable launches.\u003c\/p\u003e\n\u003cp\u003eKeeping uniform quality across 40+ global facilities is complex and costly, requiring ongoing CAPA programs and capital spend that compress margins and increase operational risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on the US Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAround 55% of Sun Pharma Industries' consolidated revenue came from the United States in FY2024, leaving the company highly exposed to US regulatory and pricing shifts.\u003c\/p\u003e\n\u003cpa major change in us drug pricing policy or tighter fda scrutiny could cut margins sharply a impact the would reduce consolidated revenue by roughly quick math\u003e\n\u003cp\u003eThis concentration forces constant monitoring of North American legal and political developments, including Medicare negotiations and state-level reforms, which can affect sales and valuation.\u003c\/p\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Generic Price Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite specialty growth, about 40% of Sun Pharmaceutical Industries’ FY2024 revenue came from standard generics, which face steep price erosion.\u003c\/p\u003e\n\u003cp\u003eIn the US, aggressive rivals and buyer consolidation have driven double‑digit annual price declines in some categories—up to 25% in certain off‑patent segments in 2023.\u003c\/p\u003e\n\u003cp\u003eThat erosion forces Sun Pharma to launch dozens of ANDAs (abbreviated new drug applications) yearly just to hold revenue; in 2024 the company filed ~30 ANDAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Legal and Litigation Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSun Pharma faces frequent patent litigations and antitrust suits; in 2024 the company disclosed over 30 active legal cases, raising recurring legal expenses and operational risk.\u003c\/p\u003e\n\u003cp\u003eThese cases create uncertainty over exclusivity for flagship drugs like ILUMYA (guselkumab) and Cequa; adverse rulings could cut revenues—Sun Pharma reported INR 9,820 crore pharma sales in FY2024, so a single lost exclusivity could swing hundreds of crores.\u003c\/p\u003e\n\u003cp\u003eLegal defeats can bring fines and early generic entry, compressing margins and market share; the company booked INR 210 crore in legal provisions in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30 active cases in 2024\u003c\/li\u003e\n\u003cli\u003eINR 9,820 crore pharma sales FY2024\u003c\/li\u003e\n\u003cli\u003eINR 210 crore legal provisions FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Challenges from Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSun Pharma’s aggressive M\u0026amp;A strategy has improved scale but raises integration risk: since 2010 the company closed over 25 deals, and delayed IT and process harmonization has caused one-time costs and slower margin recovery in some units.\u003c\/p\u003e\n\u003cp\u003eMerging disparate systems and cultures across India, US, and Europe created temporary inefficiencies; in FY2024 Sun Pharma’s EBITDA margin dipped to ~21.5% partly on acquisition-related expenses.\u003c\/p\u003e\n\u003cp\u003eMissed synergies can hit earnings—management in 2024 revised expected annual run-rate synergies down by about 10% for certain deals, showing execution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25+ deals since 2010 — integration complexity\u003c\/li\u003e\n\u003cli\u003eFY2024 EBITDA ~21.5% — acquisition costs contributed\u003c\/li\u003e\n\u003cli\u003e2024 synergy revision — ~10% downward adjustment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory hits cost $150M+, delay US injectables; FY24 sales INR 9,820cr, EBITDA ~21.5%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory hits (FDA warnings\/import alerts) raised remediation costs \u0026gt;$150m in 2023–24 and delayed US launches; FY2024 revenue rose 7% but US injectable rollouts lagged. FY2024: 55% revenue from US, 40% from generics; ~30 active legal cases, INR 210 crore legal provisions; FY2024 pharma sales INR 9,820 crore; FY2024 EBITDA ~21.5% (M\u0026amp;A drag).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue share FY2024\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales FY2024\u003c\/td\u003e\n\u003ctd\u003eINR 9,820 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal provisions FY2024\u003c\/td\u003e\n\u003ctd\u003eINR 210 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemediation costs 2023–24\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive legal cases 2024\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA FY2024\u003c\/td\u003e\n\u003ctd\u003e~21.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eSun Pharma Industries SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You’re viewing a live preview of the real document included in your download; the complete, detailed version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752322937209,"sku":"sunpharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sunpharma-swot-analysis.png?v=1772239512","url":"https:\/\/growthsharematrix.com\/products\/sunpharma-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}